The study reveals SGLT-2is are linked to fewer COPD exacerbations in type 2 diabetes, suggesting a need for further clinical trials to confirm these findings.
Novel Agent Promising as Add-On Epilepsy Treatment
A novel selective potassium channel opener appeared promising against focal-onset seizures when given atop other epilepsy medications, according to a phase IIb trial. Treatment with
October 10, 2023